Hydrocodone-Combination Products Rescheduled from C-III to C-II -- A Healthcare Provider’s Guide to Compliance

A CPhA Webinar

September 15, 2014 • 6:30 pm – 7:30 pm PST

Speaker:  Tony J. Park, Pharm.D., J.D.
Attorney at Law, California Pharmacy Lawyers, Law Office of Tony J. Park, Inc.

The Drug Enforcement Administration (DEA) has announced that all Hydrocodone Combination Products (HCPs) will be rescheduled from C-III to C-II effective October 6, 2014. This change will impact how HCPs are prescribed and dispensed in California because the requirements for prescribing and refilling C-II drugs are more restrictive than for C-III medications. This “up scheduling” is a major change for California, where according to CURES, over 1 billion dosage units of HCPs were dispensed last fiscal year in California.  

Learning Objectives:
  1. Identify the policy rationale behind the DEA's rescheduling Hydrocodone-Combination Products (HCPs) from C-III to C-II.
  2. Illustrate real-world practical effects on refills of new and existing prescriptions for HCPs.
  3. Discuss subsequent inter-professional relationship changes between prescribers and pharmacists.
  4. Evaluate how pharmacists' corresponding responsibility works after this change.

This program is targeted to pharmacists.

 Registration Fees** Registration Fee
Received by September 12, 2014
CPhA Member   $49

**Registration fees are non-refundable and non-transferrable under any circumstances.**

The California Pharmacists Association (#0113) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Upon completing an evaluation form, participants will be awarded 1 hour (0.1 CEUs) of Continuing Pharmacy Education Credit.  A statement of credit will not be issued.  Participants may log onto the CPE monitor website using their individual log in to download their statement of credit.  Please allow 4 weeks for processing of CPE credits to the CPE monitor.  UAN: 0113-0000-14-047-L03-P